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Abstract
Background. More than half of pediatric tumors of central nervous system (CNS) primarily originate 
in the posterior fossa and are conventionally treated with radiation therapy (RT).
Objectives. The objective of this study was to establish whether corpus callosum volumes (CCV) and 
whole brain volumes (WBV) are correlated and to determine the impact of whole-brain low- vs high-dose 
RT on brain parenchymal volume loss as assessed using each technique.
Material and methods. Of the 30 identified children (6–12 years) with newly diagnosed posterior fossa 
tumors treated with cranial RT, including focal and whole-brain RT, suitable imaging was obtained for 23. 
Radiotherapy regimens were the following: no whole-brain RT (Group 1, n = 7), low-dose whole-brain RT 
(<30 Gy, Group 2, n = 9) and high-dose whole-brain RT (>30 Gy, Group 3, n = 7) in addition to focal boost. 
Magnetic resonance images (MRIs) were analyzed at baseline and follow-up (median 14 months). The CCVs 
were manually segmented on midline sagittal slice (n = 23), while WBVs were segmented semi-automatically 
using Freesurfer (n = 15). This was done twice (6-month interval) for all baseline CCV measurements and 
5 randomly selected WBV measurements to establish measurement reproducibility. Correlations between 
CCV and WBV were investigated and percentage of children demonstrating reduction in CCV or WBV noted.
Results. Correlation between baseline CCV and WBV was not significant (p = 0.37). Measurement repro-
ducibility was from 6% to –9% for CCV and from 4.8% to –1.2% for WBV. Among the children studied, 
30.4% (7/23) had >9% reduction in CCV at follow-up, while 33.3% (5/15) had >1.2% reduction in WBV. 
Five of 7 patients with CCV loss were not picked up by WBV measurements. Similarly, 3 of 5 patients with 
WBV loss were not picked up by CCV measurements.
Conclusions. The CCV and the WBV are unrelated and may indicate different brain parenchymal losses 
following RT. Up to a third of posterior fossa tumors treated with RT have measurable CCV or WBV loss; 
incidence was equivalent in low- vs high-dose whole-brain RT.
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Introduction
More than half of pediatric tumors of the central ner-
vous system (CNS) primarily originate in the posterior 
fossa and are conventionally treated with radiation ther-
apy (RT).1 Such therapy is extremely effective and has led 
to an increase in long-term survivorship. However, this 
treatment induces neurotoxicity, manifesting as various 
forms of motor and cognitive long-term impairment, and 
is problematic in individuals in whom there is a long life 
expectancy: quality of  life in children surviving treat-
ment of CNS tumors is recognized as being of vital im-
portance.2,3 Neurobehavioral morbidity is a late outcome 
measure, with limited management options, which is why 
early objective indicators of likely motor or cognitive deficit 
are increasingly sought in order to implement appropriate 
management strategies early.3
Magnetic resonance imaging (MRI) has revolutionized 
anatomic assessments of the normal and diseased brain 
and has enabled characterization and monitoring of struc-
tural changes within the brain resulting from RT. Vari-
ous degrees of parenchymal volume loss and generalized 
white matter signal changes have been reported in children 
treated for medulloblastoma (MDL).4–7 Most studies used 
a fully automated hybrid neural network segmentation 
as well as a classification method to quantitatively derive 
volumes of brain parenchyma from these images.4,7,8 Vol-
umes of the corpus callosum (CC) have also been advo-
cated as a surrogate to quantify volumes of neuroparen-
chyma, because the nearly 180 million myelinated axons 
within this white matter commissure make it susceptible 
to radiation-induced damage.5,9 Nevertheless, a correla-
tion between CC volume (CCV) and whole brain volume 
(WBV) has not been demonstrated. The purpose of this 
study, therefore, was to establish whether CCVs and WBVs 
are correlated and to determine the impact of low- vs high-
dose RT on brain parenchymal volume loss as assessed 
using each technique.
Material and methods
Patients
Approval for this study was obtained from the Institu-
tional Review Board. Informed consent from the parents 
was waived.
We searched the pediatric oncology database of the Roy-
al Marsden Hospital (Sutton, London, UK) regarding a pe-
riod from 2000 to 2013 and identified 30 children between 
the age of 6 and 12 with newly diagnosed posterior fossa 
tumors, who were treated with cranial RT and in whom 
baseline (pre-RT) and follow-up (at least 6 months after 
treatment) MRI scans were available. Radiotherapy regi-
mens were either focal to the posterior fossa only or includ-
ed whole-brain RT at low (<30 Gy) or high (>30 Gy) dose.
Children below the age of 6 and those above the age 
of 12 were excluded from the study to ensure the similar 
age of our cohort. Other exclusion criteria were the fol-
lowing: 1)  radiological evidence of  surgery-related in-
tracranial bleeding (excluding asymptomatic, resolving 
hemorrhagic changes associated with recent surgery and 
the presence of punctate hemorrhage in the tumor), 2) any 
disease or condition that disabled compliance according 
to the appropriate radiation regimen, 3) prior diagnosis 
of malignancy and disease during the last imaging follow-
up, 4) previous cranial irradiation, 5) prior systematic anti-
cancer therapy, and 6) images with artefact that precluded 
brain parenchymal volume measurements.
MRI evaluation
Selection of the MRI scans for the 2nd timepoint was 
based on the completeness of image data available. Selected 
images where anonymized and placed in a Cancer Research 
UK (CRUK) Cancer Imaging Centre repository.
All images were visually inspected for quality. T2-
weighted images, pre- and post-contrast T1-weighted 
images and fluid attenuated inversion recovery and dif-
fusion weighted imaging/apparent diffusion coefficient 
maps were reviewed for each patient. The MRI scans were 
retrospectively and quantitatively analyzed by a specialist 
pediatric neuroradiologist and a biomedical scientist. Both 
readers were blind to group membership and the timepoint 
when the scans were taken.
Corpus callosum volume measurement
The anonymized images were opened in OsiriX imag-
ing Software (Pixmeo, Geneva, Switzerland) and a region 
of interest (ROI) was manually drawn on the mid-sagittal 
slice of T1-W images. Manual segmentations of CC were 
retrospectively performed by a pediatric radiologist with 
5 years of experience in pediatric brain MRI. The CCV 
was calculated using the FMRIB Software Library’s (FSL) 
stats command (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL). 
To  account for differences in  acquisition, the  volume 
of ROI was normalized by slice thickness.10 Six months 
after the initial ROIs were drawn, a 2nd set of CC ROIs 
were manually drawn by the original observer on each mid-
sagittal images to establish repeatability of the method.
Brain volume measurement
A mask of each patient’s brain was generated using the au-
torecon1 command in FreeSurfer v. 5.3 (https://surfer. 
nmr.mgh.harvard.edu).11 Each brain mask was then manu-
ally corrected by a trained biomedical scientist with 5 years 
of experience in pediatric neuroimaging. The brain masks 
were transformed into halfway space and further masked 
to ensure that only regions within the field of view at both 
timepoints were included in the volume analysis. Whole 
Adv Clin Exp Med. 2020;29(3):331–337 333
brain volumes were calculated by summing the voxels 
within the brain mask using FMRIB Software Library’s 
(FSL) stats command (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/
FSL). The MRI examinations of 5 patients were randomly 
selected from the dataset and measurements repeated 
6 months later to establish reproducibility of the method.
Statistical analysis
Statistical analysis was performed using Prism v. 7.0 
software (GraphPad Software, San Diego, USA). Descrip-
tive statistics were used to summarize the measurements. 
As the data were non-parametric, a Spearman’s rank cor-
relation tested the association between CCV and WBV.
The intra-observer repeatability for each of the measure-
ment techniques – absolute CCV or WBV – were assessed 
using a Bland–Altman method to calculate 95% confidence 
intervals (95% CIs) of the measurement. A p-value of less 
than 0.05 was considered significant. The  percentage 
reduction in CCV and WBV beyond these 95% CIs was 
assumed to represent real reductions beyond measure-
ment variability. The number of patients in each group 
that exceeded the measurement reproducibility limits was 
noted, but small numbers precluded meaningful statistical 
comparisons.
Results
Patients’ characteristics
Images of 23 children with complete data were included 
in final analyses. The cohort consisted of 17 males and 
6 females with a median age of 10 years (range: 6–12 years) 
at the time of diagnosis. Out of 23 children, 7 were diag-
nosed with high-risk MDL (MDL HR), 9 with standard-risk 
MDL (MDL SR), 3 with ependymoma, 3 with low-grade 
glioma (LGG), and 1 with atypical teratoid rhabdoid tumor 
(ATRT). Children diagnosed with MDL and ependymoma 
had received adjuvant treatment. Those with MDL had also 
received craniospinal irradiation with boost to the poste-
rior fossa and chemotherapy, whereas patients diagnosed 
with gliomas had not (Table 1).
Of 23 children, 7 received focal RT to the posterior fossa 
only (group 1), 9 were treated additionally with whole-
brain RT of 23.4 Gy in 13 fractions of 1.8 Gy (classified 
here as low-dose RT of <30 Gy – group 2), while the other 
7 received >30 Gy to the whole brain and were considered 
high-dose patients (5 received whole-brain RT of 36 Gy 
in 20 daily fractions of 1.8 Gy, while 2 received 39 Gy in 30 
fractions of 1.3 Gy to the posterior fossa – group 3).
Intra-observer measurement variability
Reproducibility estimates for the CCV ranged from 6% 
to −9% (Fig. 1A). The 95% CI for absolute CCV ranged from 
+0.48 cm3 to –0.77 cm3. The WBV values had a smaller 
variability ranging from 4.8% to −1.2% (Fig. 1B); absolute 
values ranged from +5.5 cm3 to −1.5 cm3.
Comparison of corpus callosum and brain 
volume measurements as indicators 
of brain parenchymal loss
Measurements at follow-up were performed in a range 
from 6 to 96 months after RT (median: 14 months, lower 
quartile (LQ): 10 months, upper quartile (UQ): 60 months).
Poor image quality made the derivation of the automated 
WBV segmentation error-prone, so that WBV measure-
ments were obtainable in 15 out of 23 patients. Absolute 
CCV values for 23 children at both timepoints (baseline 
and follow-up), and WBV values in 15 children at those 
timepoints are summarized in Table 2. At baseline, CCV 
values ranged from +4.4 cm3 to −11.0 cm3 (median: 8.1 cm3), 
Table 1. Patient characteristics: age, tumor type, radiation dose, time 
interval between the end of RT and the follow-up MRI. All patients 
underwent surgical resection prior to RT
ID Age [years] DGN
WB RT dose 
[Gy]
Time interval 
[months]
 1 10 MDL HR >30  6
 2 10 MDL SR <30 14
 3  9 MDL SR <30 73
 4  9 LGG 0 21
 5 11 MDL HR >30  9
 6 12 EPND 0 27
 7  9 MDL SR <30 48
 8  9 MDL SR <30 11
 9 10 MDL SR <30 60
10 11 MDL SR <30  9
11  7 MDL HR >30 12
12  8 ATRT 0 10
13 10 MDL HR >30 13
14 10 MDL SR <30 60
15  8 LGG 0  6
16  6 MDL HR >30 38
17 10 MDL SR <30 83
18  8 LGG 0 96
19 10 EPND 0 80
20 11 MDL SR <30 74
21 11 MDL HR >30 12
22 11 MDL HR >30 10
23  6 EPND 0  6
RT – radiotherapy; MRI – magnetic resonance imaging; ID – patients 
anonymized number; DGN – diagnosis/tumor type; WB RT dose – RT 
dose to whole brain: 0 (only focal RT), <30 Gy or >30 Gy; time interval 
– time in months between the end of RT and the follow-up MRI; MDL HR 
– high-risk medulloblastoma; MDL SR – standard risk medulloblastoma; 
ATRT – atypical teratoid rhabdoid tumor; EPND – ependymoma; 
LGG – low-grade glioma.
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while WBV values ranged from 695.1 cm3 to 1,364.3 cm3 
(median: 1,157.8 cm3). Correlation between baseline CCV 
and WBV was not significant (r = 0.25, p = 0.37; Fig. 2).
At follow-up, CCV values ranged from 4.2 cm3 to 9.5 cm3 
(median: 7.5 cm3). Seven out of 23 patients (30.4%) had 
a greater than 9% reduction in CCV at the 2nd timepoint, 
meaning a real reduction beyond measurement variabil-
ity (Fig. 3). At follow-up, WBV ranged from 718.0 cm3 
to 1,400.7 cm3 (median: 1,144.0 cm3). Five out of 15 pa-
tients (33.3%) had a greater than 1.2% reduction in WBV 
at the 2nd timepoint, indicating a real reduction beyond 
measurement variability.
Fig. 1. A. Bland–Altman plots showing intra-observer reproducibility and upper and lower 95% CIs (dotted lines) of manually delineated corpus callosum 
volumes (CCV). B. Bland–Altman plots showing intra-observer reproducibility and upper and lower 95% CIs (dotted lines) of automated whole brain 
segmentations (whole brain volume (WBV)); LoA – limits of agreement.
Table 2. Corpus callosum volume (CCV) and whole brain volume (WBV) measurements performed by the same observer twice at baseline and twice 
at follow-up (FU)
ID Baseline CC vol 1 [cm3]
FU CC 
vol 1 [cm3]
Baseline CC 
vol 2 [cm3]
FU CC 
vol 2 [cm3]
Baseline 
WBV 1 
[cm3]
FU WBV 1 
[cm3]
Baseline 
WBV 2 
[cm3]
FU WBV 2 
[mm3]
Percentage 
change CCV
Percentage 
change WBV
 1 8.2 8.1 8.4 8.1 −1.6
 2 8.1 8.4 8.4 8.2 947.7 990.2 934.5 996.5 3.4 4.5
 3 9.0 7.9 9.3 7.5 1,119.4 1,083.5 1,087.7 1,071.4 −13.6 −3.2
 4 8.8 7.2 8.8 7.4 −21.2
 5 8.4 7.7 8.5 7.6 −9.2
 6 6.8 6.2 6.8 6.3 −8.8
 7 9.5 9.6 9.5 9.5 1,166.8 1,186.0 1,129.1 1,160.1 1.0 1.6
 8 10.0 6.8 11.0 6.9 1,242.3 1,256.4 −46.9 1.1
 9 10.9 8.5 11.2 8.5 1,308.1 1,311.0 1,283.5 1,277.1 −29.2 0.2
10 6.8 6.8 6.9 6.8 0.0
11 7.3 7.1 7.4 7.2 −2.1
12 6.4 6.7 6.3 6.6 3.3
13 8.1 7.5 8.1 7.6 695.1 718.0 −7.4 3.3
14 7.4 8.3 8.6 8.3 1,304.9 1,096.8 10.8 −15.9
15 6.7 6.5 6.8 6.6 1,157.7 1,160.6 1,164.78 1,159.4 −1.8 0.3
16 6.2 5.3 6.2 5.2 −17.0
17 7.0 7.7 7.1 7.7 1,319.2 1,331.0 9.5 0.9
18 4.4 4 4.4 4.2 1,054.1 977.3 −9.7 −7.3
19 5.8 5.9 5.7 5.8 1,049.0 1,059.7 0.7 1.0
20 8.0 8.3 8.0 8.2 1,338.7 1,400.7 3.0 4.6
21 6.9 7 6.8 7.1 1,144.4 1,122.2 1.1 −1.9
22 8.7 7.9 8.6 8.1 1,364.3 1,330.2 −9.2 −2.5
23 8.91 9.1 8.98 9.05 1,146.2 1,143.9 2.1 −0.2
Baseline CC vol 1 – first measurement of CCV at diagnosis; FU CC vol 1 – first measurement of CCV at follow-up; Baseline CC vol 2 – repeated measurement 
of baseline CCV at diagnosis; FU CC vol 2 – repeated measurement of CCV at follow-up; Baseline WBV 1 – first measurement of the WBV at diagnosis; 
FU WBV 1 – first measurement of the WBV at follow-up; Baseline WBV 2 – repeated measurement of the WBV at diagnosis; FU WBV 2 – repeated 
measurement of the WBV at follow-up.
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Five out of 7 patients who were recognized as having 
CCV loss at follow-up were not picked up by the WBV mea-
surements. Similarly, 3 out of 5 patients identified as hav-
ing WBV loss at follow-up were not picked up by the CCV 
measurements, confirming the poor correlation between 
the 2 assessments of brain parenchymal loss.
Corpus callosum and WBV loss  
in low- vs high-dose radiation regimens
Of the 7 patients with CCV loss greater than measure-
ment variability, 2 were in group 1, 3 in group 2 and 2 
in group 3. Of the 5 patients with WBV loss greater than 
measurement variability, 1 was in group 1, 2 in group 2 and 
2 in group 3. The mean CCV loss was −5.1 in group 1, −6.9 
in group 2 and −5.5 in group 3, while for WBV the values 
were −1.6, −0.8 and −0.3, respectively.
Discussion
To our knowledge, this study is  the  first to evaluate 
the impact of RT on brain parenchyma in children using 
2 different techniques for quantifying brain volume. Our 
study showed that both CCV and WBV decrease after RT 
in up to a third of the children. Importantly, however, this 
study has shown that CCV does not correlate with WBV, 
so that significant reductions in these measurements were 
seen in different individuals. They may represent different 
ways of estimating brain parenchymal volume loss and 
should not be assumed to be interchangeable.
In  this small cohort of  patients, it  was not possible 
to demonstrate the dose distribution of RT in relation 
to the CC to establish whether a greater dose was received 
by this structure in those patients demonstrating the pro-
found effects of white matter loss within this structure.
The CCV has been used to quantify white matter loss 
in a variety of oncologic and non-oncologic applications. 
A reduced CC area was noted among children with adre-
noleukodystrophy, an effect of demyelination.12 Similar 
results have been observed in patients with attention deficit 
hyperactivity disorder, and among those with Williams 
syndrome.13–15 In oncology, white matter damage was ob-
served primarily in children with MDL (as it is the most 
common malignant solid tumor in children) and CCV was 
used to detect white matter loss.4,9 Palmer et al. described 
a decrease in the CCV in 35 MDL patients following cra-
niospinal irradiation.9 Other reports on  white matter 
volume also show that the volume of normal-appearing 
white matter decreases in children treated for MDL with 
craniospinal irradiation.4 Data from the present study 
Fig. 3. Nine-year old patient with standard-risk 
medulloblastoma (SR MDL). Figures showing 
region of interest delineating the corpus 
callosum (CC) on a mid-sagittal T1W image 
(top row, A) and a mask segmenting the whole 
brain to derive a whole brain volume (WBV; 
bottom row, B) The cerebrospinal fluid (CSF) 
spaces are excluded in B
Fig. 2. Scatter plot showing the relationship between the measurements 
of corpus callosum volume (CCV) and whole brain volumes (WBV)
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is consistent with these previous reports. The CCV mea-
surements have also been used in children with primitive 
neuroectodermal tumors treated with high-dose thiotepa 
after hyperfractionated accelerated craniospinal radio-
therapy (HART), revealing mild to severe neuroparenchy-
mal volume loss following intensive sequential high-dose 
therapy with thiotepa given after HART regimen.5 This 
confirmed previous results from a similar study, but where 
a different method of estimating brain volume was used.6
Linear increases in white matter volumes, occurring dur-
ing normal maturation, have been documented in a large-
scale study of 145 healthy individuals aged between 4 and 
20 years.13 The size of the CC also increases with age into 
early adulthood: this has been demonstrated in a study 
of 109 healthy subjects aged 7–32 years.16,17 The growth 
of CC is regarded as the direct result of myelination of cal-
losal axons present at birth. Therefore, a decline in CCV and 
WBV is opposite to what would be expected with normal 
maturation and is likely to be directly related to the effects 
of RT. In the timeframe of this study, where follow-up times 
were lengthy and patient growth and maturation would have 
occurred, it may well be that increases in CCV (and even 
in WBV) as a result of maturation would have masked any 
treatment-related reduction in CCV and WBV. Neverthe-
less, the 7 patients who showed CCV loss were followed 
up between 9 and 73 months (median: 21 months), while 
the 5 patients with WBV loss underwent follow-up imaging 
between 10 and 96 months (median: 60 months), indicating 
that follow-up time is not a primary confounding factor here.
Measurement error was greater for CCV than for WBV, 
but this is unsurprising as it depended on manual delinea-
tion rather than a computer-based automated process,  albeit 
one that required manual correction. Manual segmenta-
tion is highly intensive and time-consuming, can be prone 
to errors, and may suffer from both inter- and intra-rater 
variability.18 In several studies, automation has improved 
the reliability of ROI delineation and hence of the derived 
measurements.19,20 Nevertheless, manual measurement 
of CCV enabled us to exclude artifacts from areas of surgi-
cal resection, which can potentially affect the assessments. 
However, an accurate outlining of the CC remains a chal-
lenge. One of the factors that may affect the actual accuracy 
of measurement is the impact of RT on CC irregularity 
of size and shape in relation to other brain structures.21–23 
Another challenge for precisely outlining the CC may result 
from its decreased signal intensity as maturation of the axo-
nal cytoskeleton occurs. Signal intensity of the CC decreases 
during childhood and adolescence, thereby reducing image 
contrast between the CC and surrounding brain paren-
chyma, which may have affected outlining in our cohort 
who were mainly above the age of 8.16
The  Freesurfer-based approach employed for WBV 
measurements was more robust than the approach for 
segmenting the CC, as it reduced the potential for rater 
bias. The resulting whole-brain segmentations also in-
cluded more tissue, minimizing the effect of any variability. 
However, performing the measurements was laborious 
and time-consuming, as  extensive manual correction 
of the masks was required. Even with semi-automated seg-
mentation, the time required for each mask was around 
3 h. This meant that it was only feasible to perform the re-
peatability study in 5 cases, although ideally all patients 
should have been included.
There are several limitations of  this study. Firstly, its 
retrospective nature meant that time after RT was vari-
able (6–96 months), although we included only those pa-
tients in whom a reasonable time following treatment had 
elapsed (6 months). Nevertheless, this meant that we could 
not control neither for ongoing effects of RT nor for brain 
maturation that may have confounded the measurements. 
Secondly, the imaging was performed using a variety of pro-
tocols, which meant that differences in T1- and T2-weighting 
would have affected image contrast and the conspicuity 
of the structures being outlined, leading to measurement 
variability. To avoid these types of errors, we outlined se-
quences on the sagittal T1-W and repeated the measure-
ment after 6 months to verify measurement repeatability. 
Because of the retrospective nature of this study, variations 
in protocols meant that imaging parameters such as in-plane 
resolution also varied between patients and timepoints. 
This variation in protocols, combined with a restricted field 
of view and variable image quality, resulted in the misclas-
sification of tissue in the automated brain segmentation. 
As a result, extensive manual correction of the segmenta-
tions was required. In addition to this, the field of view used 
for the images resulted in the lateral portions of the brains 
being clipped. We compensated for the clipping by only con-
sidering brain regions that were included at both timepoints. 
Finally, because we only selected patients in whom paired, 
reasonably good quality imaging studies were available, our 
sample size was small and resulted in a low statistical power.
In summary, our study has confirmed a decline in both 
CCV and WBV values in around 1/3 of the cases follow-
ing cranial RT in children, but this decline was not re-
lated to radiation dose. However, this also suggests that 
both these measurements may not be used interchange-
ably, and may actually be sensitive to different factors. 
Both measurements, however, were relatively robust and 
even manually delineated CCV measurements would be 
expected to detect volume decreases of more than 9%. 
The appropriate measurement method should be selected, 
and its variability established when using CCV or WBV 
assessments in clinical trials.
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